Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01798485 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
A Phase 3 study, sponsored by Synta Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 696
- Enrollment target
NCT01798485: Clinical Trial Phase 3 study, sponsored by Synta Pharmaceuticals.
NCT01798485 is a Phase 3 study that was terminated before completion, run by Synta Pharmaceuticals. The registered enrollment target is 696 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01798485, a Phase 3 study, was terminated before completion, sponsored by Synta Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 696 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.
Primary Outcome
Overall survival (OS) was measured from the date of randomization to the date of death from any cause.
Interventions
- DRUG Docetaxel
- DRUG Ganetespib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 696 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Why NCT01798485 stopped before completion
NCT01798485 is an interventional study that assigns participants to a tested intervention. The registered 696 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01798485 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01798485 about?
NCT01798485 is a clinical study titled "A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC". The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.
What is the current status of trial NCT01798485?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 696 participants. The study started on 2013-04. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01798485?
The interventions under investigation include: Docetaxel (DRUG), Ganetespib (DRUG).
Who is sponsoring clinical trial NCT01798485?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01798485's enrollment target sits among peer trials
696 518th of 2000 higher than 1,483 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05417594 · 695 participants · Phase 1
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- NCT06801834 · 695 participants · Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- NCT03136094 · 698 participants · NA
Suicide in Urban Natives: Detection and Networks to Combat Events
- NCT04928846 · 698 participants · Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia